U.S. Markets close in 2 hrs 55 mins

Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Amgen Inc. AMGN announced that it has entered into an agreement with Japanese pharmaceutical company Kyowa Kirin Co to jointly develop and commercialize KHK4083 for the treatment of atopic dermatitis (“AD”).

KHK4083 is a potential first-in-class anti-OX40 fully human monoclonal antibody which is being developed by Kyowa Kirin for AD and potential other autoimmune diseases.

Per the agreement, Amgen will be responsible for the manufacture and commercialization of KHK4083 throughout the world except in Japan, while Kyowa Kirin will retain all rights to KHK4083 in the country. Meanwhile, Kyowa Kirin will be eligible to receive an upfront payment of $400 million from Amgen and future contingent milestone payments worth up to an additional $850 million, as well as significant royalty payments on future global sales of the product, if approved.

Per the press release, Kyowa Kirin will co-promote KHK4083 with Amgen in the United States and will have opt-in rights to co-promote the candidate in ex-U.S. markets, including Europe and Asia.

Shares of Amgen have gained 3.5% so far this year against the industry’s decrease of 4.1%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

Notably, in February 2021, Kyowa Kirin announced that the double-blind and placebo-controlled phase II study, which evaluated KHK4083 for treating patients with moderate-to-severe AD, met its primary endpoint. The study was conducted in the United States, Canada, Germany and Japan.

Per the company, nearly 30 million people around the world are affected with moderate-to-severe AD. Hence, if successfully developed and upon potential approval, KHK4083 can help Amgen diversify its portfolio in treating inflammatory diseases.

We note that several companies are developing medicines to treat AD. Sanofi/Regeneron Pharmaceuticals’ REGN Dupixent is approved for treating AD. Meanwhile, AbbVie’s ABBV Rinvoq (upadacitinib) and Eli Lilly’s LLY Olumiant (baricitinib) are currently under review in the United States for the treatment of AD.

Zacks Rank

Amgen currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Time to Invest in Legal Marijuana

If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027.

After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%

You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.

Today, Download Marijuana Moneymakers FREE >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

Amgen Inc. (AMGN) : Free Stock Analysis Report

AbbVie Inc. (ABBV) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research